Abstract
Introduction We investigated the interplay between infections and APOE4 on brain glucose hypometabolism, an early preclinical feature of Alzheimer’s Disease (AD) pathology.
Methods Multivariate linear regression analysis was performed on 1,509 participants of the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The outcomes were the rank-normalized hypometabolic convergence index (HCI) and statistical regions of interest (SROI) for AD and mild cognitive impairment (MCI). Further, the HCI and its change in the presence and absence of APOE4 were evaluated.
Results Infections were associated with greater hypometabolism [0.15, 95% CI: 0.03, 0.27, p=0.01], with a more pronounced effect among APOE4 carriers, indicating an interaction effect. A higher HCI (0.44, p=0.01) was observed in APOE4 carriers with multiple infections, compared to (0.11, p=0.08) for those with a single infection, revealing a dose-response relationship. The corresponding estimates for the association of infections with SROI AD and SROI MCI were -0.01 (p=0.02) and -0.01 (p=0.04) respectively.
Conclusion Our findings suggest that infections and APOE4 jointly contribute to brain glucose hypometabolism and AD pathology, supporting a “multi-hit” mechanism in AD development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the National Institutes of Healths National Institute on Aging (NIA/NIH) grants R01AG076019 and R01AG062623. This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA/NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Duke University Health System issued approval for this study (Protocol IDs Pro00109279 and Pro00105389). All participants provided written informed consent. ADNI studies follow Good Clinical Practices guidelines, the Declaration of Helsinki, and United States regulations (U.S. 21 CFR Part 50 and Part 56).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in this manuscript were obtained from the publicly available ADNI database (adni.loni.usc.edu). The ADNI database contains anonymized patient information, making it a secure data repository.
Abbreviations
- AD
- Alzheimer’s disease
- AIC
- Akaike Information Criterion
- APOE
- Apolipoprotein E
- Aβ
- Amyloid βeta
- FDG
- 18F-fluorodeoxyglucose
- GxE
- Gene-environment interaction
- GWAS
- Genome-wide association studies
- HSV
- Herpes Simplex Virus
- %INCMSE
- Percent Increase in Mean Squared error
- IQR
- Interquartile Range
- PET
- Positron Emission Tomography
- pTau
- Phosphorylated Tau
- SD
- Standard Deviation
- SNP
- Single Nucleotide Polymorphism
- SROI
- Statistical Region of Interest
- NECTIN2
- Nectin Cell Adhesion Molecule 2 (gene)
- PUD
- Peptic Ulcer Disease
- UTI
- Urinary Tract Infection
